Conectar
by Cristina J. Y. Lee, Joshua Petimar, Amanda B. Zeitlin, Caroline Collis, Lauren Cleveland, Aviva A. Musicus, Anna H. Grummon
Restaurants are increasingly adopting ecolabels to highlight environmentally friendly menu offerings. However, it remains unclear which ecolabel design is the most effective at encouraging consumers to select these items. This study aimed to determine which of 4 common ecolabel formats are perceived as most effective at encouraging selection of environmentally sustainable foods. We conducted an online experiment with 2,169 US adults in August 2023. Participants were randomized to 1 of 5 label formats, including a control format (e.g., QR code) and 4 ecolabel formats: text-plus-icon, text-only, icon-only, or numeric ecolabels. Participants viewed 3 label variations of their randomly assigned label format. Participants rated each label variation on perceived effectiveness for encouraging environmentally sustainable food choices (primary outcome) and other label reactions (e.g., thinking about environmental impacts; secondary outcomes) on 5-point scales. All ecolabels were perceived as more effective at encouraging environmentally sustainable food choices than the control labels (range of average differential effects [ADEs]=.26 to .82, psInternational pilot projects focusing on next-generation sequencing in newborn screening (NBS), that is, genomic NBS (gNBS), have been established thanks to continuous therapeutic progress and the massive development of new genetic technologies with rapidly decreasing costs. Given the highly encouraging results of the French SeDeN project regarding anticipated acceptability among professionals and parents, it is now appropriate to launch a similar pilot project in France, in collaboration with other international initiatives under the International Consortium on Newborn Sequencing framework.
PERIGENOMED is a large-scale project designed to provide the first concrete evidence on the relevance of gNBS in France. It includes two clinical trials. We present here the design chosen for the first clinical trial (PERIGENOMED-CLINICS 1). PERIGENOMED-CLINICS 1 aims to assess the feasibility, real-world acceptability, psychosocial impact and organisational pathways of panel-based genomic newborn screening in France, involving 2500 participants. Solo-GS targeting two lists of gene–disease dyads responsible for treatable (list 1; 400 genes, 171 diseases/group of diseases) or actionable (list 2 optional; 407 genes, 218 diseases/group of diseases) rare and severe early-onset diseases will be proposed in five health institutions. Ancillary social and impact studies will also be included.
All study procedures have been reviewed and approved by relevant French ethics committees and regulatory authorities (CPP Est II-2024-A02224-43, 1 January 2025). Results of the project will be disseminated through peer-reviewed publications, national and international conferences, and public engagement initiatives, in coordination with stakeholders.
FreshRSS 